Introduction: Who Should Undergo Diagnostics and When

If you notice any unusual changes in your breasts, it’s important to see a healthcare provider as soon as possible. Many people wonder when they should seek diagnostic testing, and the answer depends on both symptoms and screening recommendations. Regular breast cancer screenings are essential because breast cancer doesn’t always cause noticeable changes that you can see or feel.^[1]

You should consider seeking medical attention if you experience changes in your breast’s size or shape, discover a new lump or hardened area in or near your breast or armpit that doesn’t change with your menstrual cycle, notice skin changes affecting your breast or nipple (such as dimpling, puckering, scaling, itching, or unusual discoloration), experience nipple discharge including bloody or clear fluid, or observe a nipple that pulls inward.^[1] These symptoms don’t automatically mean you have cancer, as many of these changes occur with noncancerous conditions as well. This is exactly why diagnostic testing is so important—it helps distinguish between harmless and serious conditions.

Women with certain risk factors may need to start screenings earlier or undergo testing more frequently. These risk factors include inherited genetic mutations like BRCA1 or BRCA2, a personal or family history of breast cancer (especially in close relatives such as parents, siblings, or children), and long-term exposure to high levels of estrogen or progesterone—which can happen if you started your period very early or entered menopause late. Some forms of hormone therapy can also increase your risk.^[1]

It’s worth noting that HER2-negative and HER2-positive breast cancers have identical symptoms, so your doctor cannot tell which type you have just by examining you.^[2] This means that specialized testing on a tissue sample is always necessary to determine your exact type of breast cancer and guide your treatment plan.

Diagnostic Methods

Diagnosing HER2-negative breast cancer involves several steps, starting with initial screening and moving toward more specific testing to understand the exact nature of the cancer cells. The diagnostic process helps doctors not only confirm that cancer is present but also understand important characteristics of the cancer cells, which are called biomarkers. These biomarkers guide treatment decisions.^[1]

Tissue Sample Collection

To determine whether breast cancer is HER2-negative, doctors need to examine a small piece of your tumor tissue. They obtain this sample either during a biopsy (a procedure where a needle or small surgical tool removes tissue) or during surgery if you’ve already had a tumor removed.^[2] A biopsy is often the first step after an abnormal mammogram or physical exam finding, while surgical samples come from procedures like lumpectomy or mastectomy.

The tissue sample is sent to a laboratory where specialists analyze it to look at the cancer cells under a microscope and perform additional tests to identify specific proteins and receptors on the cell surface. This detailed examination tells doctors exactly what kind of breast cancer you have.

HER2 Status Testing

Once the tissue sample reaches the laboratory, specialists run tests to check for the presence of HER2 protein. HER2 stands for human epidermal growth factor receptor 2, which is a protein that helps control how breast cells grow and repair themselves. In healthy cells, HER2 works normally, but when cancer cells make too much of it, the cancer becomes more likely to multiply and spread.^[2]

If your test shows that your cancer cells aren’t making a lot of extra HER2, your doctor will tell you that your breast cancer is HER2-negative. This classification is crucial because it tells your healthcare team which treatments will or won’t work for you. Treatments that target HER2 proteins won’t be effective if your cancer is HER2-negative, so your doctor will suggest different treatment options.^[2]

Hormone Receptor Testing

Along with checking HER2 status, doctors also test for other important proteins called hormone receptors. These receptors respond to hormones in your blood, specifically estrogen and progesterone. Sometimes doctors refer to these separately as estrogen receptors (ER) and progesterone receptors (PR), but they often discuss all the different receptors together when describing your cancer.^[2]

Your HER2-negative cancer will be classified as either hormone receptor-positive (HR-positive/HER2-negative) or hormone receptor-negative (HR-negative/HER2-negative). If your cancer is negative for HER2 and both types of hormone receptors, it’s called triple-negative breast cancer.^[2] About 70% of breast cancers are HR-positive/HER2-negative, while only about 10 to 15% are HR-negative/HER2-negative or triple-negative.^[2]

Understanding your complete receptor status—both HER2 and hormone receptors together—gives you and your doctors vital information about the biology of your cancer. This knowledge helps doctors decide which treatment is best to try first and what backup options you have if you need to try something different later.^[2]

Additional Genetic Testing

In some cases, your doctor may look at other factors beyond HER2 and hormone receptors, including genetic changes in your cancer cells or other characteristics that could affect how quickly the cancer is likely to grow or spread.^[2] While there isn’t a specific mutation that causes HER2-negative breast cancers in particular, inheriting gene mutations like BRCA1 or BRCA2 increases your overall risk of developing breast cancer.^[1]

Imaging and Staging Tests

Beyond testing the cancer cells themselves, doctors use various imaging techniques to understand the size and location of your tumor and whether the cancer has spread. These tests help determine the stage of your cancer—information that’s just as important as knowing your HER2 status. Common imaging tests include mammography, ultrasound, MRI scans, CT scans, and bone scans, depending on your individual situation and what doctors need to learn about your cancer.

The combination of tissue analysis (showing HER2 status and hormone receptors) and imaging (showing stage and spread) gives your medical team a complete picture of your cancer. This comprehensive understanding allows them to create a treatment plan tailored specifically to your situation.

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or new ways of using existing treatments for breast cancer. If you’re considering joining a clinical trial, you’ll need to undergo specific diagnostic tests to determine if you qualify. These tests serve as standard criteria for enrolling patients and ensuring that the study results are accurate and meaningful.

Confirmed HER2-Negative Status

The most fundamental requirement for entering a HER2-negative breast cancer clinical trial is documented proof that your cancer is indeed HER2-negative. This means you must have had tissue testing that clearly shows your cancer cells don’t contain high levels of the HER2 protein. Clinical trials typically require this testing to be recent and performed using standardized laboratory methods to ensure accuracy and consistency across all study participants.

Hormone Receptor Status Documentation

Many clinical trials for HER2-negative breast cancer are designed specifically for either hormone receptor-positive or hormone receptor-negative (triple-negative) subtypes. Therefore, you’ll need clear documentation of whether your cancer cells have estrogen and progesterone receptors. This information determines which clinical trials you’re eligible for, as treatments being studied often target specific receptor combinations.

Disease Stage and Spread Assessment

Clinical trials usually enroll patients at specific stages of cancer. Some trials focus on early-stage disease that hasn’t spread beyond the breast, while others study advanced or metastatic breast cancer (cancer that has spread to other parts of the body). You’ll need imaging tests and sometimes additional biopsies to document exactly where your cancer is located and whether it has spread to lymph nodes or other organs. These assessments help researchers ensure they’re studying treatments in the right patient population.

Previous Treatment History

Many clinical trials have requirements about what treatments you’ve received in the past. Some trials are only open to patients who haven’t had any treatment yet, while others specifically enroll people whose cancer has returned after previous therapy. Your medical records documenting all previous treatments—including surgery, chemotherapy, radiation, and hormone therapy—will be reviewed to confirm your eligibility.

Genetic Testing for Certain Trials

Some clinical trials target very specific genetic characteristics of cancer cells. For these studies, you might need additional genetic testing beyond the standard HER2 and hormone receptor tests. For example, trials studying PARP inhibitors often require testing to see if you have mutations in the BRCA1 or BRCA2 genes. Other trials might look for different genetic markers that could predict whether a particular experimental treatment will work.

Overall Health Assessment

Before enrolling in a clinical trial, you’ll undergo tests to assess your overall health and how well your organs are functioning. These typically include blood tests to check your liver and kidney function, heart tests to ensure your heart is strong enough for certain treatments, and performance status evaluations to measure how well you can carry out daily activities. These assessments protect your safety by ensuring that you’re healthy enough to receive the experimental treatment being studied.

The diagnostic requirements for clinical trials are more extensive than standard care because researchers need detailed, standardized information to understand how new treatments work. While this means more testing, participating in clinical trials gives you access to potentially beneficial new treatments that aren’t yet widely available.